[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity
Acrivon Therapeutics, Inc.'s Chief Operating Officer, Eric Devroe, had 613 shares of Common Stock withheld on May 14, 2026, to cover tax obligations related to restricted stock unit vesting. The shares were valued at $1.92 each for this administrative tax-withholding disposition, which is not an open-market sale. Following this transaction, Devroe directly holds 73,972 Common Stock shares, maintaining his equity position after satisfying the required tax liability.
How this was made
The 30-second read
Why it matters
Since the transaction is not an open-market sale, it is unlikely to impact investor perception significantly.
Market read
Insider transactions related to tax withholding are routine and generally do not influence market sentiment or stock price.
What to watch
The transaction is routine and tied to tax obligations; it does not necessarily reflect management's outlook or future performance.
Background
The transaction involves the company's COO, Eric Devroe, withholding 613 shares for tax purposes following RSU vesting, which is a common administrative action.
Ticker impact
The insider transaction involves the company's COO, indicating potential insider confidence or liquidity considerations.
Minimal short-term impact; potential slight positive bias due to insider confidence.
The transaction is a tax-related withholding, not an open-market sale, which typically does not negatively signal management's view of the company's future.
Market effects
Limited sector impact; insider transactions are company-specific and do not significantly influence the biotech or life sciences sector.
Negligible; no regional market effects expected.
Negligible; this is a localized insider transaction with minimal global market influence.
Counterpoint
Some investors might interpret the withholding of shares as a sign of insider caution or liquidity needs, potentially signaling caution.
Key entities
- PersonEric Devroe
Chief Operating Officer of Acrivon Therapeutics, Inc.
- CompanyAcrivon Therapeutics, Inc.
Biotech company focused on cancer therapeutics.
